Znn3bq.jpeg
²é¿´: 1743  |  »Ø¸´: 10
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

PSA

ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)

[½»Á÷] NDA for tasocitinib to treat RA ÒÑÓÐ5È˲ÎÓë

Pfizer Inc. (NYSEFE), New York, N.Y.
Product: Tofacitinib (CP-690,550) (formerly tasocitinib)
Business: Autoimmune
Molecular target: Janus kinase-3 (JAK-3); Janus kinase-1 (JAK-1)
Description: Oral pan-Janus kinase (JAK) inhibitor
An NDA for tofacitinib to treat rheumatoid arthritis (RA) is
under FDA review with an Aug. 21 PDUFA date, while an MAA is
under review in the EU. The product is also under review in Japan.
In a conference call to discuss its 2Q12 earnings, Pfizer said FDA
requested additional analysis of data in the NDA for tofacitinib,
which the pharma said could cause the agency to extend its review
of the product past its PDUFA date. Specifics about the request
were not disclosed (see BioCentury, Aug. 6). Tofacitinib also is in
Phase III testing to treat moderate to severe plaque psoriasis.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) has
rights from Pfizer to co-market tofacitinib in Japan for RA and other
undisclosed indications
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

ÐÂÒ©·¢ÏÖ

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

PSA

ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)

ÒýÓûØÌû:
7Â¥: Originally posted by Ò©µÀÈË at 2012-08-20 15:39:39
TofacitinibƬ¼Á£¬¾ßÓпڷþ¸øÒ©µÄÓÅÊÆ£¬µ«tofacitinib²¢Î´Ö¤Ã÷±È¿¹Ö×Áö»µËÀÒò×ÓÒ©Îï¸ü¼ÓÓÐЧ£¬¶øÇÒÆä³¤ÆÚ°²È«ÐÔÈÔÈ»ÊÇÒ»¸öÃÕ¡£ÀýÈ磬ÓëtofacitinibÓйصĵ¨¹Ì´¼¼°¸ÎøˮƽÉý¸ßµÄ·çÏÕÊÇ·ñÒ×ÓÚ¾ÀÕý£¬ÒÖ»ò¸Ã·çÏÕÊÇ·ñÔ¤ ...

ÕâÕýÊÇ¿ª·¢ÐÂÒ©µÄ·çÏÕ°É£¬·çÏÕÖл¹ÊÇ´æÔÚ»ú»áµÄ£¡
¿Ú·þ¸øÒ©£¬ÎÒÏëÓ¦¸ÃÊÇÒ»¸öºÜ´óÓÅÊÆ°É£¡Ò©Ð§Èç¹ûÄܹ»´ïµ½ÖÎÁÆÄ¿µÄ£¬¸öÈ˾õµÃ¾Í¹»ÁË£¬µ«ÊǸ±×÷ÓÃ&²»Á¼·´Ó¦ÊÇÒ»¸öÐèÒª¿¼ÂǵĺÜÑÏÖØÎÊÌâ¡£
pfizerûÁËÁ¢ÆÕÍ×£¬¾Ý˵»¹Ö¸×ÅtofacitinibÄØ£¬¾Ý·ÖÎöʦԤ²â¸ÃÒ©ÎïµÄÊг¡Ç°¾°Ê®·Ö²»´í£¡

²»ÖªµÀδÀ´»áÔõÑù£¡

ʱ¼ä»á¸æËß´ó¼Ò´ð°¸£¬Ö»ÊÇ»òÔç»òÍí£¡
8Â¥2012-08-20 17:41:56
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 11 ¸ö»Ø´ð

cpujacs

ÈÙÓþ°æÖ÷ (ÖªÃû×÷¼Ò)

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) has rights from Pfizer to co-market tofacitinib in Japan for RA and other undisclosed indications
ÕâÖÖºÏ×÷ÊDz»Êǽ«À´µÄÒ»ÖÖÇ÷ÊÆ
3Â¥2012-08-20 13:15:10
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

PSA

ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)

ºÏ×÷¿ª·¢£¬Í¦ºÃµÄºÇºÇ£¡
4Â¥2012-08-20 13:22:26
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

PSA

ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)

ÒýÓûØÌû:
5Â¥: Originally posted by Ò©µÀÈË at 2012-08-20 14:29:39
²»¿´ºÃ

Äã²»¿´ºÃtofacitinibÉÏÊУ¿»¹ÊDz»¿´ºÃºÏ×÷¿ª·¢ºÇºÇ£¡
6Â¥2012-08-20 15:29:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 297£¬¹¤¿Æµ÷¼Á? +5 ºÓÄÏũҵ´óѧ-ÄÜ 2026-04-14 5/250 2026-04-18 15:17 by Equinoxhua
[¿¼ÑÐ] ½ÓÊÜÈκε÷¼Á +5 Ò²¾ÍÊÇÀõ×Ó 2026-04-17 6/300 2026-04-18 13:57 by °®³Ôâ¹ûµÄÌÇÌÇÌ
[¿¼²©] É격/¿¼²© +3 ¿ÐÃæ°üµÄСÊ鳿 2026-04-17 4/200 2026-04-17 23:54 by ÑôÑôÑô^_^
[¿¼ÑÐ] Çóµ÷¼Á +9 СÄô°®Ñ§Ï° 2026-04-16 11/550 2026-04-17 22:34 by chixmc
[Óлú½»Á÷] ¶þ±½¼×ͪËáÀàÑÜÉúÎï 50+3 С°×°®Ö÷ÈË 2026-04-17 6/300 2026-04-17 18:47 by kf2781974
[¿¼ÑÐ] 295·ÖÇóµ÷¼Á +5 ?ÒªÉϰ¶? 2026-04-17 5/250 2026-04-17 16:51 by fenglj492
[¿¼ÑÐ] ¿ÒÇëÓÐѧУÊÕÁô +8 ¿Â»´È» 2026-04-12 8/400 2026-04-17 09:34 by Öí»á·É
[¿¼ÑÐ] ²ÄÁÏÏà¹Ø×¨Òµ344Çóµ÷¼ÁË«·Ç¹¤¿ÆÑ§Ð£»ò¿ÎÌâ×é +23 hualkop 2026-04-12 25/1250 2026-04-16 22:12 by SUSE_CL
[¿¼ÑÐ] 294Çóµ÷¼Á +14 µ­È»654321 2026-04-15 14/700 2026-04-16 21:01 by lpl364211
[»ù½ðÉêÇë] RY£ºÖйú²ú³öµÄ¿ÆÑ§À¬»øÂÛÎÄ£¬¾ø¶ÔÊýÁ¿ºÍ±ÈÀý¶¼ÊÀ½çµÚÒ» +7 zju2000 2026-04-14 18/900 2026-04-16 11:36 by »¶ÀÖËÌÒ¶Ýè
[¿¼ÑÐ] 327Çóµ÷¼Á +26 Xxjc1107. 2026-04-13 29/1450 2026-04-16 10:52 by Espannnnnol
[¿¼ÑÐ] ҩѧÇóµ÷¼Á +14 à¶¹þ¼ÓÓÍ 2026-04-14 16/800 2026-04-16 10:15 by beilsong20
[¿¼ÑÐ] 310Çóµ÷¼Á +16 666ÕæºÃ 2026-04-11 18/900 2026-04-15 13:28 by ºÚ¿Æ¼¼¿óÒµ
[¿¼ÑÐ] ¸÷λÀÏʦºÃ£¬Çóµ÷¼Á£¬±¾¿Æ211£¬Ò»Ö¾Ô¸Ìì½ò´óѧÉúÎïÓëҽҩѧ˶£¬²îÁ½Ãû¼ȡ¡£ +11 ·ÁùÁùjjj 2026-04-13 11/550 2026-04-14 16:01 by zs92450
[¿¼ÑÐ] 085408¹âµçÐÅÏ¢¹¤³Ìר˶355Ò»Ö¾Ô¸³¤´º¹â»úËùµ÷¼Á +6 Íõymaa 2026-04-13 13/650 2026-04-14 11:33 by Íõymaa
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á +24 Ò¶zilin 2026-04-13 25/1250 2026-04-14 09:20 by ÊÔ¹ÜÆÆÁÑ
[¿¼ÑÐ] 2026˶ʿµ÷¼Á_Äܶ¯_ºÓÄÏũҵ´óѧ +4 ºÓÄÏũҵ´óѧ-ÄÜ 2026-04-12 4/200 2026-04-13 22:01 by bljnqdcc
[¿¼ÑÐ] BÇø0809 £¬ÊýÒ»Ó¢Ò»£¬290 Çóµ÷¼Á +3 ãöΫ1111 2026-04-12 4/200 2026-04-13 20:35 by ѧԱJpLReM
[¿¼ÑÐ] Ò»Ö¾Ô¸Õã´óÉúÎï325·ÖÇóµ÷¼Á +9 zysheng 2026-04-12 9/450 2026-04-12 22:31 by yuyin1233
[¿¼ÑÐ] 339Çóµ÷¼Á +8 hanwudada 2026-04-11 9/450 2026-04-12 15:36 by laoshidan
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û